Long Term Documentation of the Safety and Efficacy as Well as the Effects on Work Productivity in Patients With Moderate to Severe Plaque Psoriasis Treated With HUMIRA (Adalimumab) in Routine Clinical Practice (LOTOS)
Phase of Trial: Phase IV
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Acronyms LOTOS
- Sponsors Abbott Laboratories; AbbVie
- 09 Feb 2018 Planned End Date changed from 15 Oct 2018 to 31 Oct 2020.
- 09 Feb 2018 Planned primary completion date changed from 15 Oct 2018 to 31 Oct 2020.
- 16 Oct 2017 Planned End Date changed from 15 Jan 2021 to 15 Oct 2018.